Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity

Vaccine

Volumn 29, Issue 6, 2011, Pages 1185-1193

  Ni, Jing ^a   Galani, Ioanna E ^a   Cerwenka, Adelheid ^a   Schirrmacher, Volker ^a   Fournier, Philippe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti tumor; Hemagglutinin Neuraminidase; Innate immunity; Interferon ; Newcastle Disease Virus

Indexed keywords

ALPHA INTERFERON; CD11B ANTIGEN; HN PROTEIN; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER IMMUNIZATION; CONTROLLED STUDY; EXTERNAL EAR; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HN PROTEIN; IMMUNITY; IMMUNITY, INNATE; INTERFERON TYPE I; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASMS; NEWCASTLE DISEASE VIRUS; PLASMIDS; TUMOR MICROENVIRONMENT;

EID: 78751571015     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.005     Document Type: Article

References (62)

1. Sinkovics J.G., Horvath J.C. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000, 16(1):1-15.
2. Schirrmacher V., Griesbach A., Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol 2001, 18(5):945-952.
3. Fiola C., Peeters B., Fournier P., Arnold A., Bucur M., Schirrmacher V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 2006, 119(2):328-338.
4. Zeng J., Fournier P., Schirrmacher V. Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction. J Mol Med 2002, 80(7):443-451.
5. Iorio R.M., Field G.M., Sauvron J.M., Mirza A.M., Deng R., Mahon P.J., et al. Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: receptor recognition is dependent on neuraminidase activity. J Virol 2001, 75(4):1918-1927.
6. Zeng J., Fournier P., Schirrmacher V. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int J Oncol 2004, 25(2):293-302.
7. Fournier P., Zeng J., Schirrmacher V. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. Int J Oncol 2003, 23(3):673-680.
8. Fournier P., Zeng J., Von Der Lieth C.W., Washburn B., Ahlert T., Schirrmacher V. Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus. Int J Oncol 2004, 24(3):623-634.
9. Jarahian M., Watzl C., Fournier P., Arnold A., Djandji D., Zahedi S., et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009, 83(16):8108-8121.
10. Zeng J., Fournier P., Schirrmacher V. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002, 297(1):19-30.
11. Coley W.B. Contribution to the knowledge of sarcoma. Ann Surg 1891, 14:199-220.
12. Dickey C. Review reopens old disagreements. Nat Med 2002, 8:1337.
13. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
14. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
15. Nagaraj S., Gabrilovich D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008, 68(8):2561-2563.
16. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(3):162-174.
17. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4(12):941-952.
18. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161.
19. Zou W., Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6(4):295-307.
20. Beckhove P., Schirrmacher V. Local tumor growth and spontaneous systemic T cell responses in cancer patients: a Paradox and Puzzle. The tumor microenvironment 2008, vol. 1. p. 53-76.
21. Kiessling R., Klein E., Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5(2):112-117.
22. Cerwenka A., Lanier L.L. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001, 1:41-49.
23. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2:735-747.
24. Screpanti V., Wallin R.P., Grandien A., Ljunggren H.G. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005, 42:495-499.
25. Walzer T., Dalod M., Robbins S.H., Zitvogel L., Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force." Blood 2005, 106:2252-2258.
26. Martín-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN- for T(H)1 priming. Nat Immunol 2004, 5:1260-1265.
27. Terme M., Ullrich E., Delahaye N.F., Chaput N., Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008, 9:486-494.
28. Ni J., Nolte B., Arnold A., Fournier P., Schirrmacher V. Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. Vaccine 2009, 27(40):5480-5487.
29. Moschos S., Kirkwood J.M. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev 2007, 18(5-6):451-458.
30. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14(1):7-17.
31. Cull V.S., Broomfield S., Bartlett E.J., Brekalo N.L., James C.M. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther 2002, 9:1369-1378.
32. Ertel C., Millar N.S., Emmerson P.T., Schirrmacher V., von Hoegen P. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 1993, 23(10):2592-2596.
33. Termeer C.C., Schirrmacher V., Bröcker E.B., Becker J.C. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 2000, 7(2):316-323.
34. Ni J., Nolte B., Vandermeulen G., Préat V., Scherman D., Schirrmacher V., et al. Ear pinna: A privileged DNA electroporation site for inducing strong Th1 immune responses. Open Cancer Immunol J 2009, 2:1-13.
35. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
36. Biron C.A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol 1999, 2(4):374-381.
37. Parronchi P., De Carli M., Manetti R., Simonelli C., Sampognaro S., Piccinni M.P., et al. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992, 149(9):2977-2983.
38. Brinkmann V., Geiger T., Alkan S., Heusser C.H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 1993, 178(5):1655-1663.
39. Nguyen K.B., Salazar-Mather T.P., Dalod M.Y., Van Deusen J.B., Wei X.Q., Liew F.Y., et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002, 169(8):4279-4287.
40. Zhang X., Sun S., Hwang I., Tough D.F., Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998, 8(5):591-599.
41. Tough D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004, 45(2):257-264.
42. von Hoegen P., Zawatzky R., Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol 1990, 126(1):80-90.
43. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272(5270):1947-1950.
44. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005, 202(5):637-650.
45. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gewert D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003, 4(10):1009-1015.
46. Albini A., Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-147.
47. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M.A., Vallejo C., et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79:2320-2328.
48. Takanami I., Takeuchi K., Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 2001, 121:1058-1063.
49. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
50. Villegas F.R., Coca S., Villarrubia V.G., Jiménez R., Chillón M.J., Jareño J., et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
51. Zingoni A., Sornasse T., Cocks B.G., Tanaka Y., Santoni A., Lanier L.L. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 2004, 173(6):3716-3724.
52. Wong S.B., Bos R., Sherman L.A. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008, 180(5):3122-3131.
53. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties and mechanisms of immune suppression. Semin Cancer Biol 2006, 16(1):53-65.
54. Maier T., Holda J.H., Claman H.N. Murine natural suppressor cells in the newborn, in bone marrow, and after cyclophosphamide. J Immunol 1999, 143:491-498.
55. Vieweg J., Su Z., Dahm P., Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007, 13(2 Pt 2):727s-732s.
56. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58(1):49-59.
57. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
58. Nausch N., Galani I.E., Schlecker E., Cerwenka A. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 2008, 112:4080-4089.
59. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010, 40(1):22-35.
60. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32(6):790-802.
61. Ilkovitch D., Lopez D.M. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009, 69(13):5514-5521.
62. Ni J., Schirrmacher V., Fournier P. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. Vaccine 2010, 28(42):6891-6900.